famotidine has been researched along with Acute Coronary Syndrome in 4 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Acute Coronary Syndrome: An episode of MYOCARDIAL ISCHEMIA that generally lasts longer than a transient anginal episode that ultimately may lead to MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Little is known about the efficacy of proton pump inhibitors compared with H(2) receptor antagonists in preventing adverse upper gastrointestinal complications in patients with acute coronary syndrome (ACS) or ST elevation myocardial infarction (STEMI) receiving aspirin, clopidogrel, and enoxaparin or thrombolytics." | 9.16 | Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction. ( Chan, K; Chu, WM; Keung, KK; Kng, C; Kwan, A; Lam, KF; Lau, YK; Li, A; Ng, FH; Tunggal, P; Wong, BC, 2012) |
| "It remains unclear whether concomitant use of omeprazole attenuates platelet function as compared with that of famotidine in patients with acute coronary syndromes (ACS) who receive clopidogrel." | 9.16 | Influence of omeprazole and famotidine on the antiplatelet effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes: a prospective, randomized, multicenter study. ( Endo, T; Fukui, K; Hibi, K; Himeno, H; Kimura, K; Morita, S; Sugano, T; Tsukahara, K; Umemura, S; Yano, H, 2012) |
| "Little is known about the efficacy of proton pump inhibitors compared with H(2) receptor antagonists in preventing adverse upper gastrointestinal complications in patients with acute coronary syndrome (ACS) or ST elevation myocardial infarction (STEMI) receiving aspirin, clopidogrel, and enoxaparin or thrombolytics." | 5.16 | Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction. ( Chan, K; Chu, WM; Keung, KK; Kng, C; Kwan, A; Lam, KF; Lau, YK; Li, A; Ng, FH; Tunggal, P; Wong, BC, 2012) |
| "It remains unclear whether concomitant use of omeprazole attenuates platelet function as compared with that of famotidine in patients with acute coronary syndromes (ACS) who receive clopidogrel." | 5.16 | Influence of omeprazole and famotidine on the antiplatelet effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes: a prospective, randomized, multicenter study. ( Endo, T; Fukui, K; Hibi, K; Himeno, H; Kimura, K; Morita, S; Sugano, T; Tsukahara, K; Umemura, S; Yano, H, 2012) |
| "Patients with acute coronary syndrome or elective percutaneous coronary interventions treated with aspirin and clopidogrel cotherapy were randomized to receive esomeprazole 20 mg daily or famotidine 40 mg daily." | 5.15 | Effect of esomeprazole versus famotidine on platelet inhibition by clopidogrel: a double-blind, randomized trial. ( Chan, FK; Lam, KF; Lau, YK; Ng, FH; Tunggal, P, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tunggal, P | 2 |
| Ng, FH | 2 |
| Lam, KF | 2 |
| Chan, FK | 1 |
| Lau, YK | 2 |
| Chu, WM | 1 |
| Li, A | 1 |
| Chan, K | 1 |
| Kng, C | 1 |
| Keung, KK | 1 |
| Kwan, A | 1 |
| Wong, BC | 1 |
| Yano, H | 1 |
| Tsukahara, K | 1 |
| Morita, S | 1 |
| Endo, T | 1 |
| Sugano, T | 1 |
| Hibi, K | 1 |
| Himeno, H | 1 |
| Fukui, K | 1 |
| Umemura, S | 1 |
| Kimura, K | 1 |
| Horiuchi, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Influence of Esomeprazole on Antiplatelet Action of Clopidogrel Associated With Aspirin[NCT01062516] | Phase 4 | 100 participants (Anticipated) | Interventional | 2010-01-31 | Completed | ||
| Famotidine Compared With Esomeprazole in the Prevention of Ulcer Complications in Patients With Acute Coronary Syndrome or Myocardial Infarction[NCT00683111] | Phase 4 | 500 participants (Anticipated) | Interventional | 2008-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for famotidine and Acute Coronary Syndrome
| Article | Year |
|---|---|
Effect of esomeprazole versus famotidine on platelet inhibition by clopidogrel: a double-blind, randomized trial.
Topics: Acute Coronary Syndrome; Anti-Ulcer Agents; Blood Platelets; Clopidogrel; Double-Blind Method; Esome | 2011 |
Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction.
Topics: Acute Coronary Syndrome; Aged; Anti-Ulcer Agents; Aspirin; Chi-Square Distribution; Clopidogrel; Dou | 2012 |
Influence of omeprazole and famotidine on the antiplatelet effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes: a prospective, randomized, multicenter study.
Topics: Acute Coronary Syndrome; Aged; Anti-Ulcer Agents; Aspirin; Blood Platelets; Clopidogrel; Drug Antago | 2012 |
1 other study available for famotidine and Acute Coronary Syndrome
| Article | Year |
|---|---|
Proton-pump inhibitors could be innocent when used concomitantly with clopidogrel.
Topics: Acute Coronary Syndrome; Anti-Ulcer Agents; Aspirin; Blood Platelets; Clopidogrel; Famotidine; Femal | 2012 |